医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Maxinovel Pharmaceuticals Announces the Presentation of Its Orally Active PD-1/PD-L1 Inhibitors in 2018 AACR

2018年02月27日 AM12:10
このエントリーをはてなブックマークに追加


 

GUANGZHOU, China

Maxinovel Pharmaceuticals today announces that it will present preclinical results of its orally active PD-1/PD-L1 inhibitors as a single agent or combination with Epacadostat, Celebrex, Cisplatin and CTLA-4, respectively. The presentation will be held in 2018 AACR in Chicago, USA. The details are as follows:

Title: Novel small molecule inhibitors of PD-1/PD-L1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel and Canonical Targets

Session Date and Time: Tuesday April 17, 2018 8:00am-12:00pm

Location: McCormick Place South, Exhibit Hall A, Poster Section 35

Poster Board Number: 17

Permanent Abstract Number: 3851

About Maxinovel Pharmaceuticals, Inc:

Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info: www.maxinovel.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005313/en/

CONTACT

Maxinovel Pharmaceuticals
Ms. Pingjing Zhang
pjzhang@maxinovel.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Terns Pharmaceuticalsがエリン・クワーク医師を最高医学責任者に任命したと発表
  • New Leaders Join CDISC 2019 Board of Directors
  • EBM Technologies Announces Industry Breakthrough with First FDA Cleared System for Remote Diagnostic Reading of Radiological Images
  • キアゲン、肺がんEGFR検査のコンパニオン診断薬としての承認を日本で取得
  • Diaceutics Opens Asian Hub to Capitalize on Growing Market